BD Boosts U.S. Manufacturing of Critical Medical DevicesBD Boosts U.S. Manufacturing of Critical Medical Devices

Becton Dickinson & Co. is set to make additional investments in its U.S. manufacturing network to add capacity for critical medical devices.

“BD has a longstanding history as a leading U.S. manufacturer of medical devices, including 200 years of collective experience in manufacturing syringes, needles, and IV catheters at our facilities in Nebraska, Connecticut, and Utah,” a BD company spokesperson said, in response to MD+DI’s request for comments.

New needle and syringe production lines have been installed at the Franklin Lakes, NJ-based company’s plants in Connecticut and Nebraska. One of them is already fully operational, and additional lines are expected within the coming months. “While we have done numerous expansions of all of these facilities over the years, these most recent investments include the installation of new production lines within the existing footprint of our facilities, boosting our capacity to meet U.S. healthcare needs,” said the company’s spokesperson.

The new lines will increase BD’s capacity of domestically manufactured safety-engineered injection devices by more than 40% and conventional syringes by more than 50 percent, according to BD. The company also said that these additional manufacturing capabilities will enable it to add hundreds of millions of units annually to support hospital procedures, vaccinations, medication preparation, and drug delivery to patients.

Related:General Biophysics to Explore Therapeutic Potential of Xenon Gas for Neurological Diseases

“The growing demand for these essential products, particularly in light of recent market disruptions caused by foreign suppliers, highlights the importance of a reliable healthcare supply chain,” the BD spokesperson continued. “Our latest investments are a continuation of our commitment to domestic production and support of U.S. healthcare.”

BD has hired more than 215 full-time employees at its facilities in Nebraska and Connecticut to support this increased production.

The company also plans to invest more than $30 million in 2025 to expand its IV line manufacturing capacity at its plant in Utah, to support its catheter solutions. This follows the company's 2024 investment of more than $2 million for IV line improvements that resulted in increased IV catheter output by more than 40 million units annually.

"Domestic manufacturing is crucial for ensuring a resilient supply of essential health care devices," said Eric Borin, president of Medication Delivery Solutions at BD, in prepared remarks. "By expanding our production capacity, we are not only meeting the critical needs of patients and providers, but we also are reinforcing our commitment to the nation's healthcare infrastructure."